Brexit contingency plans revealed
This article was originally published in OTC Bulletin & The Rose Sheet
Contingency plans set out by the UK government outlining how medicines and medical devices would be regulated and tested in the event of a ‘no deal’ exit by Britain from the European Union (EU) at the end of March 2019 have been welcomed by the Proprietary Association of Great Britain (PAGB).
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.